fluoxetine has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether SSRIs impact disease progression, fluoxetine (Prozac, 5 or 10 mg/kg) was administered to mutant superoxide dismutase 1 (SOD1) mice during one of three age ranges: neonatal [postnatal day (P)5-11], adult presymptomatic (P30 to end stage), and adult symptomatic (P70 to end stage)." | 1.40 | Effect of fluoxetine on disease progression in a mouse model of ALS. ( Heckman, CJ; Kajtaz, E; Kocevar, EJ; Koschnitzky, JE; Lukas, TJ; Mayers, WF; Quinlan, KA; Siddique, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koschnitzky, JE | 1 |
| Quinlan, KA | 1 |
| Lukas, TJ | 1 |
| Kajtaz, E | 1 |
| Kocevar, EJ | 1 |
| Mayers, WF | 1 |
| Siddique, T | 1 |
| Heckman, CJ | 1 |
| Sawada, J | 1 |
| Yamashita, T | 1 |
| Aizawa, H | 1 |
| Aburakawa, Y | 1 |
| Hasebe, N | 1 |
| Kwak, S | 1 |
| Le Ber, I | 1 |
| Dubois, B | 1 |
1 review available for fluoxetine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
[Frontotemporal dementia].
Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Alzheimer Disease; Amyotrophic Lateral Sclerosis | 2007 |
2 other studies available for fluoxetine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Effect of fluoxetine on disease progression in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; | 2014 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; | 2009 |